Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Executive Summary

FDA considering public statement reflecting its view that biosimilars not deemed interchangeable will not be substituted at pharmacy, but the extent such a statement would limit payer-driven practice remains in question.


Related Content

Humira Biosimilar Interchangeability: The Race Begins
Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Biosimilar Prescribing Decisions May Depend Upon Disease State
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar Interchangeability Requirements Pushed At Inflectra Review


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts